ArticleOncology letters2017
MicroRNA-139 targets fibronectin 1 to inhibit papillary thyroid carcinoma progression.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Identification and validation of hub genes involved in papillary thyroid carcinoma progression.BMC cancer · 2026Article
- BLNIMDA: identifying miRNA-disease associations based on weighted bi-level network.BMC genomics · 2022Article
- MicroRNAs in Papillary Thyroid Cancer: What Is New in Diagnosis and Treatment.Frontiers in oncology · 2021Review
- Review
- MicroRNA-3690 promotes cell proliferation and cell cycle progression by altering DKK3 expression in human thyroid cancer.Oncology letters · 2020Article
- miR-98-5p promotes apoptosis and inhibits migration and cell growth in papillary thyroid carcinoma through Bax/Caspase-3 by HMGA2.Journal of clinical laboratory analysis · 2020Article
- MiR-376c-3p targets heparin-binding EGF-like growth factor (HBEGF) to inhibit proliferation and invasion in medullary thyroid carcinoma cells.Archives of medical science : AMS · 2020Article
- MiR-345-5p inhibits tumorigenesis of papillary thyroid carcinoma by targeting SETD7.Archives of medical science : AMS · 2020Article
- BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.World journal of surgical oncology · 2019Article
- Analysis of microarray data for identification of key microRNA signatures in glioblastoma multiforme.Oncology letters · 2019Article
- MicroRNA-432 is downregulated in cervical cancer and directly targets FN1 to inhibit cell proliferation and invasion.Oncology letters · 2019Article
- miRNA-766 induces apoptosis of human colon cancer cells through the p53/Bax signaling pathway by MDM4.Experimental and therapeutic medicine · 2019Article
- Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes.NPJ systems biology and applications · 2019Article
- The LncRNA LINC00963 facilitates osteosarcoma proliferation and invasion by suppressing miR-204-3p/FN1 axis.Cancer biology & therapy · 2019Article
- Signaling Complexity Measured by Shannon Entropy and Its Application in Personalized Medicine.Frontiers in genetics · 2019Article
- An 8 miRNA-Based Risk Score System for Predicting the Prognosis of Patients With Papillary Thyroid Cancer.Technology in cancer research & treatmentArticle
Corrections and comments
- Retraction · 2022-05-31Author Unresponsive · Concerns/Issues about Data · Duplication of/in Image · Investigation by Journal/Publisher · Paper Mill · · see also: https://pubpeer.com/publications/A8AC8045BE16E162A9443B52CF5E53
- Retracted
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer is the most common tumour of the endocrine system, and its incidence rate has markedly increased over the past several decades. Aberrantly expressed microRNAs (miRNAs) are reportedly involved in the formation and progression of papillary thyroid carcinoma (PTC) by regulating their target genes. Thus, miRNAs may be potential molecular biomarkers for the prediction and prognosis of PTC, and also as novel therapeutic targets for patients with PTC. miR-139 has recently been reported to be aberrantly expressed in several types of cancer. However, the expression levels, biological functions and the associated molecular mechanism of miR-139 in PTC have not been clearly elucidated. The results of the present study revealed that miR-139 expression was downregulated in PTC tissues and cell lines when compared with adjacent normal tissues and normal human thyroid cells, respectively. The restoration of miR-139 expression suppressed cellular proliferation and invasion in PTC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.